The Impact of IL-6 and IL-10 Gene Polymorphisms in Diffuse Large B-Cell Lymphoma Risk and Overall Survival in an Arab Population: A Case-Control Study.
Arab population
IL-10
IL-6
diffuse large B-cell lymphoma
single nucleotide polymorphism
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
07 Feb 2020
07 Feb 2020
Historique:
received:
03
12
2019
revised:
10
01
2020
accepted:
05
02
2020
entrez:
13
2
2020
pubmed:
13
2
2020
medline:
13
2
2020
Statut:
epublish
Résumé
B-cell lymphomas can be classified as Hodgkin and non-Hodgkin lymphomas. Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin Lymphoma (NHL). The incidence of NHL is variable and affected by age, gender, racial, and geographic factors. There is strong evidence that the immune-regulatory cytokines have a major role in hematologic malignancies. In this study, we analyzed the relationship between seven single nucleotide polymorphisms (SNPs) in two selected cytokines (IL-6 rs1800795G > C, rs1800796G > C, rs1800797G > A, IL-10 rs1800871G > A, rs1800872G > T, rs1800890A > T, rs1800896T > C) and the risk and overall survival of DLBCL patients in a Jordanian Arab population. One hundred and twenty-five DLBCL patients diagnosed at King Abdullah University Hospital (KAUH) from the period 2013-2018 and 238 matched healthy controls were included in the study. Genomic DNA was extracted from formalin-fixed paraffin-embedded tissues. Genotyping of the genetic polymorphisms was conducted using a sequencing protocol. Our study showed no significant differences in the distribution of all studied polymorphisms of DLBCL between patients and controls. The IL-6 rs1800797 was the only SNP to show significant survival results, DLBCL subjects with the codominant model (GG/AG/AA) genotypes and recessive model (AA genotype in comparison with the combined GG/GA genotype) had worse overall survival (
Identifiants
pubmed: 32046104
pii: cancers12020382
doi: 10.3390/cancers12020382
pmc: PMC7072608
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Jordan University of Science and Technology
ID : 20170225
Références
Br J Haematol. 2006 Jul;134(2):180-3
pubmed: 16740140
Arch Immunol Ther Exp (Warsz). 1997;45(5-6):353-7
pubmed: 9437490
Nature. 2000 Aug 17;406(6797):782-7
pubmed: 10963608
Annu Rev Immunol. 2009;27:29-60
pubmed: 18817510
Int Immunopharmacol. 2003 Aug;3(8):1061-71
pubmed: 12860163
Nature. 1986 Nov 6-12;324(6092):73-6
pubmed: 3491322
Proc Natl Acad Sci U S A. 2005 Sep 13;102(37):13260-5
pubmed: 16150725
Nat Genet. 2004 Jun;36(6):565-74
pubmed: 15167933
J Clin Endocrinol Metab. 2004 Apr;89(4):1885-90
pubmed: 15070960
Blood. 2005 Jun 15;105(12):4894-5; author reply 4895
pubmed: 15933064
Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):588-93
pubmed: 9435236
Cancer Res. 2006 Oct 1;66(19):9771-80
pubmed: 17018637
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Nature. 2000 Feb 3;403(6769):503-11
pubmed: 10676951
J Clin Oncol. 1995 Mar;13(3):575-82
pubmed: 7884418
PLoS One. 2013 Nov 18;8(11):e79445
pubmed: 24260222
Leuk Lymphoma. 2015 Jan;56(1):163-8
pubmed: 24684230
Eur J Immunogenet. 1997 Feb;24(1):1-8
pubmed: 9043871
Science. 1992 Oct 23;258(5082):593-7
pubmed: 1411569
Hematol J. 2000;1(1):53-66
pubmed: 11920170
Leuk Lymphoma. 2017 Nov;58(11):2695-2704
pubmed: 28393658
Haematologica. 2016 Oct;101(10):1244-1250
pubmed: 27354024
Stroke. 2004 Oct;35(10):2294-300
pubmed: 15331795
J Immunol. 1995 May 1;154(9):4261-8
pubmed: 7722286
Blood. 2006 May 15;107(10):4101-8
pubmed: 16449530
Carcinogenesis. 2007 Mar;28(3):704-12
pubmed: 17056605
Annu Rev Immunol. 1992;10:295-331
pubmed: 1590989
Leuk Lymphoma. 2003 Feb;44(2):251-5
pubmed: 12688341
Nat Rev Immunol. 2005 Oct;5(10):749-59
pubmed: 16175180
Tissue Antigens. 2008 Feb;71(2):146-50
pubmed: 18201362
Gene. 2013 May 1;519(2):288-94
pubmed: 23485354
PLoS One. 2013;8(2):e56455
pubmed: 23418570
Nature. 1996 Oct 31;383(6603):787-93
pubmed: 8893001
Immunol Invest. 2015;44(3):265-78
pubmed: 25564959
Clin Cancer Res. 1997 Dec;3(12 Pt 2):2581-4
pubmed: 9815659
Int J Cancer. 2014 Dec 1;135(11):2735-9
pubmed: 24752499
J Clin Oncol. 2006 May 10;24(14):2137-50
pubmed: 16682732
Public Health Nutr. 2014 Jul;17(7):1531-7
pubmed: 23659580
Lancet Oncol. 2006 Jan;7(1):27-38
pubmed: 16389181
Cancer Res. 1992 Jun 15;52(12):3317-22
pubmed: 1596890
Blood. 2000 Oct 1;96(7):2562-7
pubmed: 11001912
Science. 1993 Sep 24;261(5129):1739-44
pubmed: 8397445
Crit Rev Microbiol. 2013 Aug;39(3):229-46
pubmed: 22866947
Lancet. 2001 Feb 17;357(9255):539-45
pubmed: 11229684
Hum Genet. 1999 Sep;105(3):253-7
pubmed: 10987653
Immunogenetics. 1997;46(2):120-8
pubmed: 9162098
Curr Opin Chem Biol. 2012 Apr;16(1-2):214-20
pubmed: 22221852
CA Cancer J Clin. 2016 Nov 12;66(6):443-459
pubmed: 27618563
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8641-5
pubmed: 1717982
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
Ann Hematol. 1995 Aug;71(2):57-63
pubmed: 7654854
Rambam Maimonides Med J. 2014 Oct 29;5(4):e0038
pubmed: 25386354
J Natl Cancer Inst Monogr. 2014 Aug;2014(48):41-51
pubmed: 25174025
Blood. 2008 Dec 15;112(13):5150-60
pubmed: 18796628
Asian Pac J Cancer Prev. 2014;15(21):9177-83
pubmed: 25422198
Hematol Oncol. 2008 Jun;26(2):98-103
pubmed: 18271063
Science. 2003 Jun 27;300(5628):2101-4
pubmed: 12829785
Haematologica. 2007 Nov;92(11):1475-81
pubmed: 18024395
Blood. 2004 May 1;103(9):3529-34
pubmed: 14701701